Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

Europe - EBR:BTLS - BE0974386188 - Common Stock

4.42 EUR
-0.04 (-0.9%)
Last: 10/16/2025, 12:27:40 PM
Fundamental Rating

2

BTLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 69 industry peers in the Chemicals industry. BTLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BTLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTLS has reported negative net income.
In the past year BTLS has reported a negative cash flow from operations.
BTLS had negative earnings in each of the past 5 years.
In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BTLS has a worse Return On Assets (-51.18%) than 91.30% of its industry peers.
BTLS's Return On Equity of -74.88% is on the low side compared to the rest of the industry. BTLS is outperformed by 86.96% of its industry peers.
Industry RankSector Rank
ROA -51.18%
ROE -74.88%
ROIC N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BTLS has been increased compared to 1 year ago.
BTLS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BTLS has an improved debt to assets ratio.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 9.08 indicates that BTLS is not in any danger for bankruptcy at the moment.
BTLS's Altman-Z score of 9.08 is amongst the best of the industry. BTLS outperforms 100.00% of its industry peers.
BTLS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.16, BTLS is doing good in the industry, outperforming 75.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 9.08
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.61 indicates that BTLS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.61, BTLS belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
A Quick Ratio of 3.61 indicates that BTLS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.61, BTLS belongs to the top of the industry, outperforming 97.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.61
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.96% over the past year.
EPS 1Y (TTM)18.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
BTLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.43% yearly.
EPS Next Y0.88%
EPS Next 2Y14.71%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BTLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BTLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.71%
EPS Next 3Y0%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (10/16/2025, 12:27:40 PM)

4.42

-0.04 (-0.9%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)09-18 2025-09-18
Earnings (Next)N/A N/A
Inst Owners21.69%
Inst Owner ChangeN/A
Ins Owners4.84%
Ins Owner ChangeN/A
Market Cap165.84M
Analysts86.67
Price Target7.58 (71.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.24%
EPS NY rev (3m)53.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)20%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.37
P/tB 8.61
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.53
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.18%
ROE -74.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.61
Altman-Z 9.08
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.97%
Cap/Depr(5y)109.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.58%
EPS Next Y0.88%
EPS Next 2Y14.71%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A
EBIT growth 1Y9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.38%
EBIT Next 3Y-3.79%
EBIT Next 5YN/A
FCF growth 1Y37.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.87%
OCF growth 3YN/A
OCF growth 5YN/A